Rainer Weber

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
    R Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    HIV Med 14:195-207. 2013
  2. doi Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
  3. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
  4. doi CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
  5. doi Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Clin Trials 10:207-14. 2009
  6. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
  7. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
  8. pmc Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27463. 2011
  9. ncbi Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 45:111-9. 2007
  10. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007

Collaborators

Detail Information

Publications62

  1. doi Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
    R Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    HIV Med 14:195-207. 2013
    ..Classification of deaths is hampered because of low autopsy rates, frequent deaths outside of hospitals, and shortcomings of International Statistical Classification of Diseases and Related Health Problems (ICD-10) coding...
  2. doi Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
    ..These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response...
  3. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
    ..Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort...
  4. doi CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
    ....
  5. doi Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Clin Trials 10:207-14. 2009
    ..We aimed to evaluate the efficacy and the impact of discontinuing and/or switching enfuvirtide on virologic and clinical parameters in clinical practice...
  6. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
    ....
  7. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
    ..Equally, this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing antibody titers...
  8. pmc Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27463. 2011
    ..Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated...
  9. ncbi Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 45:111-9. 2007
    ..Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment...
  10. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  11. ncbi Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
    ....
  12. pmc Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich Rämistrasse, 100 8091 Zürich, Switzerland
    J Virol 81:9693-706. 2007
    ....
  13. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  14. pmc Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
    ..In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity...
  15. doi Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    Sara Gianella
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Antivir Ther 16:535-45. 2011
    ..Early initiation of combination antiretroviral therapy (ART) during primary HIV-1 infection may prevent the establishment of large viral reservoirs, possibly resulting in improved control of plasma viraemia rebound after ART cessation...
  16. doi The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    J Infect Dis 204:1095-103. 2011
    ..By analyzing human immunodeficiency virus type 1 (HIV-1) pol sequences from the Swiss HIV Cohort Study (SHCS), we explored whether the prevalence of non-B subtypes reflects domestic transmission or migration patterns...
  17. doi Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1130-9. 2011
    ..We studied the influence of aging on the epidemiology of non-AIDS diseases in the Swiss HIV Cohort Study...
  18. doi Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
    ....
  19. doi Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    AIDS 25:441-51. 2011
    ..Interruptions of ART are still frequent. The long-term effect on CD4 T-cell recovery and clinical events remains unknown...
  20. doi Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1271-9. 2011
    ..We analyzed HIV-1 transmission in relation to viral and host characteristics within the Zurich primary HIV-1 infection study...
  21. doi Ageing with HIV: medication use and risk for potential drug-drug interactions
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    J Antimicrob Chemother 66:2107-11. 2011
    ..To compare the use of co-medication, the potential drug-drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥ 50 years or <50 years...
  22. ncbi Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  23. ncbi Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy
    Angela C Huttner
    University Hospital of Zurich, Zurich, Switzerland
    AIDS 21:939-46. 2007
    ..We examined the predictive factors for this phenomenon and assessed its impact on clinical progression during treatment in a large patient cohort...
  24. pmc Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy
    Marek Fischer
    University Hospital Zurich, Division of Infectious Diseases, Ramistrasse 100, 8092 Zurich, Switzerland
    Retrovirology 5:107. 2008
    ..These cells persisted during cART. Nevertheless, during the first four weeks of therapy their kinetics resembled that of productively infected cells...
  25. doi Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland
    Joëlle Nicoletti
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Swiss Med Wkly 140:w13059. 2010
    ..Thus, we aimed to determine the risk factors for this increased fluoroquinolone resistance in outpatients and inpatients with urinary tract infection (UTI) or colonisation with E. coli...
  26. doi Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 15:413-23. 2010
    ..We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability...
  27. pmc Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
    Roger D Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Clin Infect Dis 52:532-9. 2011
    ..We assessed whether the fraction of ambiguous nucleotides obtained from bulk sequencing as done for genotypic resistance testing can serve as a proxy of this parameter...
  28. doi Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection
    Helen Kovari
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 50:502-11. 2010
    ..Chronic liver disease in human immunodeficiency virus (HIV)-infected patients is mostly caused by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult to diagnose...
  29. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  30. ncbi Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 190:1979-88. 2004
    ....
  31. pmc Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
    ....
  32. doi HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    AIDS 24:1177-83. 2010
    ..To study transmission dynamics during acute infection, during the aviremic phase over the period of early antiretroviral therapy (ART) and during the phase of viral rebound after early treatment was stopped...
  33. doi Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 54:51-8. 2010
    ..This prospective study aimed to characterize the virologic and immunologic changes during monotherapy with lamivudine (3TC) in patients with limited options for a fully suppressive new therapy...
  34. ncbi Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
    Annelies S Zinkernagel
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Antivir Ther 11:131-42. 2006
    ....
  35. ncbi Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
    ..Quantitation of HCV RNA with regard to its subcellular distribution and longitudinal course is needed for better understanding of the largely unexplored in vivo dynamics and potential pathogenetic significance of HCV in PBMCs...
  36. ncbi Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    AIDS Res Hum Retroviruses 20:909-15. 2004
    ..92 versus 2.17 years, p = 0.30). In conclusion, AVN could not be attributed to time on antiretroviral treatment, but patients with AVN had histories of more severe immunosuppression and a higher body mass index than controls...
  37. doi Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
    Clin Infect Dis 51:1314-22. 2010
    ..We studied the frequency, changes over time, and determinants of unprotected sex among HIV-positive persons...
  38. ncbi Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 189:273-85. 2004
    ..Thus, residual lymphoid HIV-1 RNA in patients receiving HAART indicates attenuated viral transcription in HIV-1-infected cells that lack virion production...
  39. ncbi Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
    ..In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points...
  40. ncbi Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
    Urs Karrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Switzerland
    AIDS 19:1987-94. 2005
    ..This effect might be related to ddI toxicity since ddI exposure is substantially increased by TDF...
  41. doi Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons
    Simona Berger
    Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University of Zurich, Switzerland
    AIDS 22:767-75. 2008
    ..To determine the effects of cognitive-behavioral stress management (CBSM) training on clinical and psychosocial markers in HIV-infected persons...
  42. doi Profile of travel-associated illness in children, Zürich, Switzerland
    Thomas Hunziker
    University of Zurich Centre for Travel Medicine, World Health Organisation Collaborating Centre for Travellers Health, University of Zurich, Zurich, Switzerland
    J Travel Med 19:158-62. 2012
    ..Defining the profile of reported travel-associated illnesses will help to improve the prevention and treatment of such illnesses in children...
  43. pmc Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection
    Adrian Schmid
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 5:e13310. 2010
    ..In the current study, HIV-1 RNA transcription patterns in peripheral blood mononuclear cells (PBMC) were monitored during acute cART to assess the effect of early treatment on cellular viral reservoirs...
  44. ncbi Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Antivir Ther 8:97-104. 2003
    ..In contrast, expression of HIV-UsRNAPBMC increased during STI and consequently provides a more sensitive, albeit not absolute cellular marker of ongoing HIV-1 replication...
  45. ncbi Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Antivir Ther 9:85-95. 2004
    ..A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence...
  46. doi Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    J Infect Dis 208:1102-12. 2013
    ..2% vs 2.5%; P = .004). Conclusions. Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin-transmission vs sporadic appearance-of these variants determines their impact on ART needs to be further explored. ..
  47. ncbi Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?
    Alexander Imhof
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 41:721-8. 2005
    ..Lactic acidosis is a rare but life-threatening complication of combination antiretroviral therapy (CART). Asymptomatic or mildly symptomatic episodes of hyperlactatemia are more frequent, but their clinical relevance is unknown...
  48. pmc Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
    ..These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations...
  49. doi Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay
    Stefan P Kuster
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    J Antimicrob Chemother 62:1451-61. 2008
    ..Hospital-wide cumulative antibiograms may not sufficiently support informed decision-making for optimal treatment of hospitalized patients...
  50. doi Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
    Roger D Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 201:1488-97. 2010
    ..Sequence data from resistance testing offer unique opportunities to characterize the structure of human immunodeficiency virus (HIV) infection epidemics...
  51. ncbi Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
    ..We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure...
  52. pmc Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study
    Helen Kovari
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland
    Clin Infect Dis 56:870-9. 2013
    ..Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality...
  53. ncbi HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load
    Annette Oxenius
    Institute for Microbiology, Eidgenossische Technische Hochschule Zurich, Zurich, Switzerland
    J Infect Dis 189:1199-208. 2004
    ..Slower progression was not related to polymorphisms in CCR genes, HLA genotype, or GB virus C coinfection. These data suggest that HIV-specific T cell responses are involved in protecting the host from disease progression...
  54. ncbi Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH 809a Zurich, Switzerland
    Arch Intern Med 166:1632-41. 2006
    ..An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases...
  55. ncbi Impact of genotypic resistance testing on selection of salvage regimen in clinical practice
    Stefan Haupts
    Divisione of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Antivir Ther 8:443-54. 2003
    ..To determine whether genotypic resistance testing leads to selection of more potent drug regimens when compared to regimens based on treatment history only...
  56. ncbi When time is more than money: the allocation of time between work and leisure in HIV-infected patients
    Pedram Sendi
    Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland
    Soc Sci Med 64:2355-61. 2007
    ..e., wage rate), and that (ii) availability of non-labour income induces income effects, i.e. individuals demand more leisure time...
  57. pmc Serological response to treatment of syphilis according to disease stage and HIV status
    Damaris Fröhlich Knaute
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Clin Infect Dis 55:1615-22. 2012
    ..Serology is the mainstay for syphilis diagnosis and treatment monitoring. We investigated serological response to treatment of syphilis according to disease stage and HIV status...
  58. pmc Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey
    Alexia Cusini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 5:e14011. 2010
    ..We studied the quality of antimicrobial therapy and prophylaxis in hospitalized patients at a tertiary care hospital to plan interventions to improve the quality of antimicrobial prescription...
  59. doi Sex and gender differences in travel-associated disease
    Patricia Schlagenhauf
    University of Zurich Centre for Travel Medicine, World Health Organisation Collaborating Centre for Travellers Health, University of Zurich, Zurich, Switzerland
    Clin Infect Dis 50:826-32. 2010
    ..No systematic studies exist on sex and gender differences across a broad range of travel-associated diseases...
  60. doi Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection
    Anna Haas
    Institute of Microbiology, ETH Zurich, Zurich, Switzerland
    Gut 60:1506-19. 2011
    ..The mechanisms underlying B cell hyperactivation and the specificities of the resulting hypergammaglobulinaemia are only poorly understood...
  61. doi Influence of antiretroviral therapy on liver disease
    Helen Kovari
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland
    Curr Opin HIV AIDS 6:272-7. 2011
    ....
  62. ncbi Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1
    Christine Schraner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Clin Infect Dis 40:e120-4. 2005
    ..The skin lesions failed to respond to full treatment courses of amphotericin B, sodium stibogluconate, and liposomal amphotericin B but were successfully treated with miltefosine, an alkylphosphocholine analogue...